deferasirox has been researched along with Hypogonadism in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambrogio, AG; Baldini, M; Cassinerio, E; Mancarella, M; Marcon, A; Motta, I | 1 |
| Amendola, G; Casale, M; Cinque, P; Citarella, S; De Michele, E; Della Rocca, F; Filosa, A; Nobili, B; Palmieri, F; Perrotta, S; Pugliese, U; Ragozzino, A; Tartaglione, I | 1 |
| Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V | 1 |
| Cançado, RD; Chiattone, CS; Guerra-Shinohara, EM; Krieger, JE; Pereira, AC; Santos, PC | 1 |
1 trial(s) available for deferasirox and Hypogonadism
| Article | Year |
|---|---|
Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Bone and Bones; Bone Density; Calcium; Chelation Therapy; Child; Child, Preschool; Deferasirox; Diabetes Mellitus; Diphosphonates; Female; Humans; Hypogonadism; Hypoparathyroidism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Puberty, Delayed; Retrospective Studies; Triazoles; Vitamin D | 2014 |
3 other study(ies) available for deferasirox and Hypogonadism
| Article | Year |
|---|---|
Adrenal insufficiency: An emerging challenge in thalassemia?
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Adult; Benzoates; Blood Transfusion; Combined Modality Therapy; Deferasirox; Humans; Hypoglycemia; Hypogonadism; Hypothalamo-Hypophyseal System; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelolipoma; Pituitary-Adrenal System; Shock, Septic; Thalassemia; Triazoles | 2017 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles | 2016 |
HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox.
Topics: Benzoates; Brazil; Cation Transport Proteins; Combined Modality Therapy; Deferasirox; Exons; Gene Amplification; Hemochromatosis; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Hypogonadism; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Membrane Proteins; Phlebotomy; Polymorphism, Single Nucleotide; Receptors, Transferrin; Stroke Volume; Triazoles; Young Adult | 2010 |